Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an update.
Botanix Pharmaceuticals Limited has announced the cessation of 742,406 securities due to the lapse of conditional rights, as the conditions for these securities were not met. This cessation may impact the company’s capital structure and could influence investor perception, reflecting the challenges in meeting certain operational or strategic conditions.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology and antimicrobial products. The company is known for its innovative approach to addressing unmet needs in skin health and infection control.
Average Trading Volume: 9,510,310
Technical Sentiment Signal: Sell
Current Market Cap: A$617.7M
For a thorough assessment of BOT stock, go to TipRanks’ Stock Analysis page.